Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.68 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.62 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.62 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.62 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.60 |
| ▸ | ACHE | P22303 | 1/20 | 0.56 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.55 |
| ▸ | CCR3 | P51677 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22470259 | 0.92 | ALDH1A1 (0.62) | HTR2ASIGMAR1CACNA1G | |
| SCHEMBL22470212 | 0.87 | HTR2A (0.52) | HTR2AHDAC1HDAC8HDAC6SIGMAR1 | |
| SCHEMBL31582791 | 0.87 | HTR2A (0.66) | HTR2AHDAC1HDAC8HDAC6SIGMAR1 | |
| SCHEMBL22470199 | 0.85 | HTR2A (0.50) | HTR2AHDAC1HDAC8HDAC6SIGMAR1 | |
| SCHEMBL22470297 | 0.85 | MEN1 (0.62) | HDAC8 | |
| SCHEMBL27300983 | 0.84 | HTR2A (0.75) | HTR2ASIGMAR1ACHEOPRM1CCR3 | |
| SCHEMBL1519356 | 0.84 | HTR2A (0.75) | HTR2ASIGMAR1ACHEOPRM1CCR3 | |
| SCHEMBL22470198 | 0.83 | DPP7 (0.58) | HTR2AHDAC1HDAC8HDAC6 | |
| Hydrochloric Acid SCHEMBL1405913 | 0.83 | HTR2A (0.73) | HTR2ASIGMAR1ACHEOPRM1CCR3 | |
| SCHEMBL5367392 | 0.82 | HTR2A (0.71) | HTR2ASIGMAR1ACHEOPRM1CCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1054858-A1 | N-HYDROXY-2-(ALKYL, ARYL, OR HETEROARYL SULFANYL, SULFINYL OR SULFONYL)-3-SUBSTITUTED-ALKYL, ARYL OR HETEROARYLAMIDES AS MATRIX METALLOPROTEINASE INHIBITORS | American Cyanamid Company (US) | 2000-11-29 | — | — | EP | claimed |
| WO-1999042436-A1 | N-HYDROXY-2-(ALKYL, ARYL, OR HETEROARYL SULFANYL, SULFINYL OR SULFONYL)-3-SUBSTITUTED-ALKYL, ARYL OR HETEROARYLAMIDES AS MATRIX METALLOPROTEINASE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1999-08-26 | — | — | WO | claimed |
| US-20220151962-A1 | NOVEL INHIBITORS OF HISTONE DEACETYLASE 10 | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2022-05-19 | — | — | US | disclosed |
| WO-2020193431-A1 | NOVEL INHIBITORS OF HISTONE DEACETYLASE 10 | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2020-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220151962-A1 | NOVEL INHIBITORS OF HISTONE DEACETYLASE 10 | HDAC10, HDAC1, HDAC11 | HTR2A 4528/4885HDAC1 2/4885HDAC8 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.